摘要 |
<p>The present invention relates to a method for diagnosing prostatic adenocarcinoma (CAP) in a male human patient without requiring a biopsy. The total prostate specific antigen (PSA) level in the blood or serum of the patient is measured. If the patient has a total PSA level of between 2.5 ng/ml and 20.2 ng/ml, then the free PSA level in the blood or serum of the patient is measured. The proportion of free PSA (10) to total PSA (12) is calculated. If this proportion is less than about 7 %, then the patient is diagnosed as having CAP. The present method can also be used on patients that have a total PSA of at least 10.1 ng/ml, but have also had a negative prostate biopsy.</p> |